111 related articles for article (PubMed ID: 32946625)
1. Prostate biopsy histopathologic features correlate with a commercial gene expression assay's reclassification of patient NCCN risk category.
Greenland NY; Cowan JE; Chan E; Carroll PR; Stohr BA; Simko JP
Prostate; 2020 Dec; 80(16):1421-1428. PubMed ID: 32946625
[TBL] [Abstract][Full Text] [Related]
2. Correlation of a Commercial Genomic Risk Classifier with Histological Patterns in Prostate Cancer.
Greenland NY; Zhang L; Cowan JE; Carroll PR; Stohr BA; Simko JP
J Urol; 2019 Jul; 202(1):90-95. PubMed ID: 30810466
[TBL] [Abstract][Full Text] [Related]
3. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.
Cullen J; Rosner IL; Brand TC; Zhang N; Tsiatis AC; Moncur J; Ali A; Chen Y; Knezevic D; Maddala T; Lawrence HJ; Febbo PG; Srivastava S; Sesterhenn IA; McLeod DG
Eur Urol; 2015 Jul; 68(1):123-31. PubMed ID: 25465337
[TBL] [Abstract][Full Text] [Related]
4. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
[TBL] [Abstract][Full Text] [Related]
5. The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer.
Gaffney C; Golan R; Cantu MD; Scognamiglio T; McCarthy H; Mosquera JM; McClure TD; Barbieri CE; Robinson BD; Khani F
J Urol; 2019 Jul; 202(1):96-101. PubMed ID: 30933552
[TBL] [Abstract][Full Text] [Related]
6. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
7. Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer.
Cedars BE; Washington SL; Cowan JE; Leapman M; Tenggara I; Chan JM; Cooperberg MR; Carroll PR
J Urol; 2019 Oct; 202(4):696-701. PubMed ID: 30958742
[TBL] [Abstract][Full Text] [Related]
8. A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy.
Salmasi A; Said J; Shindel AW; Khoshnoodi P; Felker ER; Sisk AE; Grogan T; McCullough D; Bennett J; Bailey H; Lawrence HJ; Elashoff DA; Marks LS; Raman SS; Febbo PG; Reiter RE
J Urol; 2018 Sep; 200(3):564-572. PubMed ID: 29524506
[TBL] [Abstract][Full Text] [Related]
9. Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests.
Falagario UG; Beksac AT; Martini A; Cumarasamy S; Gupta A; Prasad S; Thulasidass H; Shah QN; Jayaratna I; Lewis S; Rastinehad AR; Taouli B; Cormio L; Carrieri G; Tewari AK
J Urol; 2019 Jul; 202(1):102-107. PubMed ID: 30730408
[TBL] [Abstract][Full Text] [Related]
10. NCCN Risk Reclassification in Black Men with Low and Intermediate Risk Prostate Cancer After Genomic Testing.
Seiden B; Weng S; Sun N; Gordon D; Harris WN; Barnett J; Myrie A; Jones T; Pak SY; Fudl A; Shields J; McNeil BK; Weiss JP; Smith MT; Esdaille AR; Winer AG
Urology; 2022 May; 163():81-89. PubMed ID: 34688772
[TBL] [Abstract][Full Text] [Related]
11. Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer.
Blume-Jensen P; Berman DM; Rimm DL; Shipitsin M; Putzi M; Nifong TP; Small C; Choudhury S; Capela T; Coupal L; Ernst C; Hurley A; Kaprelyants A; Chang H; Giladi E; Nardone J; Dunyak J; Loda M; Klein EA; Magi-Galluzzi C; Latour M; Epstein JI; Kantoff P; Saad F
Clin Cancer Res; 2015 Jun; 21(11):2591-600. PubMed ID: 25733599
[TBL] [Abstract][Full Text] [Related]
12. The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer.
Helfand BT; Paterakos M; Wang CH; Talaty P; Abran J; Bennett J; Hall DW; Lehman A; Aboushwareb T
PLoS One; 2022; 17(9):e0273782. PubMed ID: 36048818
[TBL] [Abstract][Full Text] [Related]
13. Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier.
Taylor AS; Morgan TM; Wallington DG; Chinnaiyan AM; Spratt DE; Mehra R
Prostate; 2020 Feb; 80(2):146-152. PubMed ID: 31737920
[TBL] [Abstract][Full Text] [Related]
14. Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score.
Brand TC; Zhang N; Crager MR; Maddala T; Dee A; Sesterhenn IA; Simko JP; Cooperberg MR; Srivastava S; Rosner IL; Chan JM; Febbo PG; Carroll PR; Cullen J; Lawrence HJ
Urology; 2016 Mar; 89():69-75. PubMed ID: 26723180
[TBL] [Abstract][Full Text] [Related]
15. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
[TBL] [Abstract][Full Text] [Related]
16. Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit.
Radtke JP; Takhar M; Bonekamp D; Kesch C; Erho N; du Plessis M; Buerki C; Ong K; Davicioni E; Hohenfellner M; Hadaschik BA
Eur Urol Focus; 2018 Jul; 4(4):540-546. PubMed ID: 28753844
[TBL] [Abstract][Full Text] [Related]
17. Does the addition of targeted prostate biopsies to standard systemic biopsies influence treatment management for radiation oncologists?
Kamrava M; Hegde JV; Abgaryan N; Chang E; Le JD; Wang J; Kupelian PA; Marks LS
BJU Int; 2016 Apr; 117(4):584-91. PubMed ID: 25684394
[TBL] [Abstract][Full Text] [Related]
18. Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy.
Yashi M; Nukui A; Tokura Y; Takei K; Suzuki I; Sakamoto K; Yuki H; Kambara T; Betsunoh H; Abe H; Fukabori Y; Nakazato Y; Kaji Y; Kamai T
BMC Urol; 2017 Jun; 17(1):47. PubMed ID: 28645325
[TBL] [Abstract][Full Text] [Related]
19. Most Gleason 8 Biopsies are Downgraded at Prostatectomy-Does 4 + 4 = 7?
Gansler T; Fedewa S; Qi R; Lin CC; Jemal A; Moul JW
J Urol; 2018 Mar; 199(3):706-712. PubMed ID: 29032296
[TBL] [Abstract][Full Text] [Related]
20. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies.
Martin DT; Ghabili K; Levi A; Humphrey PA; Sprenkle PC
Urology; 2019 Mar; 125():64-72. PubMed ID: 30552940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
